1-(戊烷-3-基)肼盐酸盐 | 221024-42-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(戊烷-3-基)肼盐酸盐
• 英文名称: (1-ethyl-propyl)-hydrazine hydrochloride
• 英文别名: 3-pentylhydrazine hydrochloride；3-pentylhydrazine HCl；1-(Pentan-3-yl)hydrazine hydrochloride；pentan-3-ylhydrazine;hydrochloride
• CAS: 221024-42-6
• 化学式: C₅H₁₄N₂*ClH
• mdl: MFCD14583114
• 分子量: 138.641
• InChiKey: CJFLBOKQFSMRMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.01
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P285,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P342+P311,P362,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H302,H312,H315,H319,H332,H335,H334
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  1-(戊烷-3-基)肼盐酸盐 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 3-Hydrazino-pentan
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS
  [FR] COMPOSES HETEROCYCLIQUES FUSIONNES

  摘要：

  公开号：

  WO2005040169A3
• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 3-戊酮 在 palladium 10% on activated carbon 溶剂黄146 、 氢气 、 盐酸 作用下， 以 乙醇 、 溶剂黄146 、 水 、 乙酸乙酯 为溶剂， 反应 55.0h， 生成 1-(戊烷-3-基)肼盐酸盐
  参考文献：
  名称：

  EP1396493

  摘要：

  公开号：

文献信息

• 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
  申请人：Hodgetts J. Kevin

  公开号：US20050070542A1

  公开（公告）日：2005-03-31

  5-aryl-Pyrazolo[4,3-d]pyrimidines, 6-aryl-Pyrazolo[3,4-d]pyrimidines and related compounds, as well as other chemically related compounds, that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  5-芳基吡唑并[4,3-d]嘧啶，6-芳基吡唑并[3,4-d]嘧啶及相关化合物，以及其他化学相关化合物，作为CRF 1受体的选择性调节剂。这些化合物在治疗多种中枢神经系统和外周障碍，特别是压力、焦虑、抑郁、心血管障碍和进食障碍方面具有用途。还提供了治疗这些障碍的方法以及包装的药物组合物。本发明的化合物还可用作CRF受体定位的探针和CRF受体结合测定中的标准。给出了在受体定位研究中使用这些化合物的方法。
• A Variation of the Fischer Indolization Involving Condensation of Quinone Monoketals and Aliphatic Hydrazines
  作者：Jinzhu Zhang、Zhiwei Yin、Patrick Leonard、Jing Wu、Kate Sioson、Che Liu、Robert Lapo、Shengping Zheng

  DOI：10.1002/anie.201207533

  日期：2013.2.4

  new twist: A one‐pot nitrous acid free, diazonium‐free, and transition‐metal‐free variation of the Fischer indole synthesis has been developed. Condensation of quinone monoketals and aliphatic hydrazine hydrochlorides afforded indoles via intermediate alkylaryldiazenes. This method will complement the classical Fischer indole synthesis by providing indoles in two steps from widely available phenols

  一个新的转折：已开发出Fischer吲哚合成的一锅无亚硝酸，无重氮和无过渡金属的变体。醌单缩酮和脂族肼盐酸盐的缩合通过中间体烷基芳基二氮烯得​​到吲哚。该方法将在温和的条件下从两步制得的苯酚中分两步提供吲哚，从而补充了经典的Fischer吲哚合成方法。
• [EN] THIAZOLYL-DIHYDRO-INDAZOLES<br/>[FR] THIAZOLYLDIHYDROINDAZOLES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009112565A1

  公开（公告）日：2009-09-17

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES FUSIONNES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005040169A2

  公开（公告）日：2005-05-06

  Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.

  某些含有融合的吡咯和吡唑的杂环化合物是用于治疗与血清素有关的疾病的血清素调节剂。
• Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
  申请人：——

  公开号：US20010025042A1

  公开（公告）日：2001-09-27

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  Corticotropin releasing factor (CRF)拮抗剂的公式（I）：1及其用于治疗精神障碍和神经系统疾病、焦虑相关障碍、创伤后应激障碍、上行性麻痹和进食障碍，以及治疗哺乳动物中与心理病理紊乱和压力相关的免疫、心血管或心脏相关疾病和结肠过敏性反应。